Vilin Bio Med
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 16 Jun 2023 – 21 Jun 2023
- Listing date
- 30 Jun 2023
- Face value
- ₹10 per share
- Issue price
- ₹30 per share
- Lot size
- 4,000 shares
- Issue type
- Fixed Price issue
- Total issue size
- ₹12 Cr
- Market cap at offer price
- ₹41.85 Cr
- Promoter holding
- 91.45% → 64.52% pre-issue → post-issue
- ISIN
- INE0L4V01013
- Registrar
- Bigshare Services Pvt.Ltd.
- Lead managers
- Inventure Merchant Banker Services Pvt.Ltd.
- Registered office
- Sy.No.115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowempally, Telangana
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Market maker | 2,08,000 | — | — |
Application size
Minimum 4,000 shares per lot, in multiples, at ₹30
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 4,000 | ₹1,20,000 |
| S-HNI (min) | 2 | 8,000 | ₹2,40,000 |
| S-HNI (max) | 8 | 32,000 | ₹9,60,000 |
| B-HNI (min) | 9 | 36,000 | ₹10,80,000 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Valuation and performance
Valuation at offer price
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 0.10 | — |
| P/E (×) | 300.00 | — |
| Market cap | — | ₹41.85 Cr |
Key performance indicators
- Return on net worth
- 1.15%
- ROCE
- 8.58%
- Debt / equity
- 0.71
- PAT margin
- 0.30%
- NAV per share
- ₹8.96
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Vilin Bio Med
Vilin Bio Med Limited, incorporated in 2005, is a pharmaceutical manufacturing company based in Roorkee, Uttarakhand, India. The company operates in the Indian pharmaceutical sector, manufacturing a range of dosage forms including oral liquids (syrups, suspensions, dry powders), tablets and capsules (beta and non-beta lactam), and external preparations. The company follows a business model of selling products in bulk to pharmaceutical manufacturers, marketers, and traders who then distribute to end customers. With an established R&D foundation and state-of-the-art manufacturing facility, the company serves customers across South, North, West, and Central India. The company's revenue for 9 months ended December 31, 2022 was ₹901.29 lakhs with net profit of ₹128.08 lakhs.
Company Analysis
from RHPVilin Bio Med Limited manufactures pharmaceutical products including oral liquids, tablets, capsules, and external preparations for bulk supply to pharmaceutical companies and traders across India.
Vilin Bio Med Limited, incorporated in 2005, is a pharmaceutical manufacturing company based in Roorkee, Uttarakhand, India. The company operates in the Indian pharmaceutical sector, manufacturing a range of dosage forms including oral liquids (syrups, suspensions, dry powders), tablets and capsules (beta and non-beta lactam), and external preparations. The company follows a business model of selling products in bulk to pharmaceutical manufacturers, marketers, and traders who then distribute to end customers. With an established R&D foundation and state-of-the-art manufacturing facility, the company serves customers across South, North, West, and Central India. The company's revenue for 9 months ended December 31, 2022 was ₹901.29 lakhs with net profit of ₹128.08 lakhs.
Objects of the Issue
- Augmenting additional working capital requirements ₹848.89 lakhs p.60
- General Corporate Purposes ₹251.11 lakhs p.60
- Issue Related Expenses ₹100.00 lakhs p.60
Issue Structure
- Total Issue
- ₹1,200.00 lakhs (40,00,000 Equity Shares at ₹30 per share)
- Fresh Issue
- ₹1,200.00 lakhs (40,00,000 Equity Shares)
- Offer for Sale
- Nil
- Price Band
- Fixed price of ₹30 per equity share
- Lot Size
- Minimum subscription is as per SEBI regulations; Market Maker Reservation Portion: 2,08,000 shares; Retail allocation minimum: ₹2,00,000
- Face Value
- ₹10 per equity share
Business Model
Contract manufacturing of pharmaceutical products (oral liquids, tablets, capsules, external preparations) on a purchase order basis, selling in bulk to pharmaceutical manufacturers, marketers, and traders without any brand name. Revenue is generated through manufacturing and sale of pharmaceutical formulations to B2B customers.
Business Segments
SWOT Analysis
- • Experienced management with industry expertise and strategic relationships(p.81)
- • State-of-the-art manufacturing facility with R&D Foundation and quality assurance(p.12)
- • Quality manufacturing focus with in-house testing laboratory(p.81)
- • Significant excess manufacturing capacity available for growth(p.84)
- • Cost leadership in pharmaceutical manufacturing(p.77)
- • Heavy dependence on top 10 customers representing bulk of revenue(p.23)
- • Dependence on limited key suppliers without formal long-term agreements(p.19)
- • No long-term agreements with customers or suppliers(p.18)
- • Significant outstanding litigations affecting operations(p.16)
- • Inability to protect intellectual property(p.22)
- • Negative cash flows in the past(p.29)
- • Growth through capacity expansion and operational efficiency(p.82)
- • Expanding customer base through geographic expansion(p.82)
- • India's growing pharmaceutical market with strong CAGR(p.12)
- • India as world's pharmacy with significant export potential(p.12)
- • Projected domestic pharmaceutical market growth to $130 billion by 2030(p.76)
- • Introduction of new high-margin products(p.63)
- • Intense competition from domestic and international players(p.23)
- • Risk of supply chain disruption and raw material unavailability(p.19)
- • Downturn in pharmaceutical industry affecting revenue(p.18)
- • COVID-19 pandemic impact on operations(p.19)
- • Regulatory changes affecting manufacturing and operations(p.21)
- • Customer payment delays affecting working capital(p.21)
- • Breakdown of manufacturing unit disrupting business(p.20)
- • Macroeconomic downturn in India affecting demand(p.30)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Sadhanala Venkata Rao | Promoter | 46.13% | 32.90% |
| D. Srinivasa Reddy | Promoter | 20.23% | 14.43% |
| Viswa Prasad Sadhanala | Promoter | 18.86% | 13.45% |
| Ramesh Reddy Sama | Promoter | 4.66% | 3.32% |
Leadership
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.